CN104293788A - SiRNA inhibiting expression of gene S100A9 and application of siRNA - Google Patents
SiRNA inhibiting expression of gene S100A9 and application of siRNA Download PDFInfo
- Publication number
- CN104293788A CN104293788A CN201410541184.2A CN201410541184A CN104293788A CN 104293788 A CN104293788 A CN 104293788A CN 201410541184 A CN201410541184 A CN 201410541184A CN 104293788 A CN104293788 A CN 104293788A
- Authority
- CN
- China
- Prior art keywords
- sirna
- group
- gene
- expression
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a siRNA inhibiting expression of a gene S100A9 and an application of the siRNA and relates to the field of molecular biology. The siRNA inhibiting the expression of the gene S100A9 is characterized in that a sequence of a positive-sense strand is 5'-GCUUCGAGGAGUUCAUCAU-3' and a sequence of an antisense strand is 5'-AUGAUGAACUCCUCGAAGC-3'. The siRNA disclosed by the invention can be used for reducing expression of the gene S100A9, inhibiting expression of a gene MMP7 in a nasopharyngeal carcinoma cell CNE1 and degrading a migration function of the nasopharyngeal carcinoma cell, so that the siRNA can be applied to research of a medicine used for treating nasopharyngeal carcinoma.
Description
Technical field
The present invention relates to biology field, specifically relate to the siRNA of suppression S100A9 genetic expression and suppressing the application in nasopharyngeal carcinoma cell CNE1 shift function.
Background technology
Nasopharyngeal carcinoma (Nasopharyngeal carcinoma NPC) is a kind of malignant tumour deriving from Nasal Epithelial Cells, more than 95% belongs to undifferentiated carcinoma type, grade malignancy is high, growth is fast, easily occur lymphoglandula or Blood route metastasis, therefore most Nasopharyngeal Carcinoma Patients is all died from the transfer of tumour and is not primary tumor.In recent years along with the develop rapidly of molecular biology and technology thereof, the generation development of nasopharyngeal carcinoma and biological behaviour thereof obtain greater advance.Multinomial research shows, S100A8 and S100A9 participates in developing of tumour, existing research and utilization iTRAQ protein quantification mark finds in conjunction with during MALDI-TOF-MS mass-spectrometric technique screening for nasopharyngeal cancer associated biomarkers, and in plasma of patients with nasopharyngeal carcinoma, S100A8 protein and S100A9 protein expression level are apparently higher than healthy population.
S100A8 albumen (Calgranulin A albumen, MRP8 albumen) and S100A9 albumen (CalgranulinB albumen, MRP14 albumen) all belong to lower molecular weight (being respectively 11kDa and 14kDa), N-terminal EF-1 and C-terminal EF-2 hand-type structure, calcium binding protein S100 protein family member, and both often form heterodimer S100A8/A9 albumen composition in calcium ion dependency mode.Recent study finds, both are at multiple former and invasive tumor, comprises cancer of the stomach, colorectal carcinoma, carcinoma of the pancreas, bladder cancer, ovarian cancer, thyroid carcinoma, mammary cancer, skin carcinoma, nasopharyngeal carcinoma rise.
The lethality of cancer is mainly because cancer cells invades surrounding tissue and can enter blood or lymphsystem and carry out far-end transfer.The reports such as Saha, with 0.2-1 μ g/ml S100A8/A9 treatments B 6F10 melanocyte, can cause and tumor cell invasion and the expression of moving relevant matrix metalloproteinase MMP, promote the migration of cell.And about the research of endogenous S100A8/A9, the reports such as Yong, the S100A8/A9 of tumour cell oneself expression also has and causes tumor cell invasion and transporting action.
In recent years RNA perturbation technique develops rapidly, is not only widely used in therapy of tumor, and is the useful tool of research gene function.Therefore the expression of S100A8/A9 in nasopharyngeal carcinoma cell CNE1 is reduced by research and design S100A8siRNA, S100A9siRNA, thus suppress the migration of nasopharyngeal carcinoma cell, there is important clinical meaning, but at present also not about the relevant report of the siRNA of suppression S100A8, S100A9 genetic expression.
Summary of the invention
Goal of the invention of the present invention is to provide the siRNA suppressing S100A9 genetic expression, and provides this siRNA application clinically further.
Object of the present invention is achieved through the following technical solutions:
There is provided the siRNA suppressing S100A9 genetic expression, its sequence is:
Positive-sense strand: 5'-GCUUCGAGGAGUUCAUCAU-3'(SEQ ID NO.5)
Antisense strand: 5'-AUGAUGAACUCCUCGAAGC-3'(SEQ ID NO.6)
Preferably, the 3' of above-mentioned S100A9siRNA sequence end overhangs two dTdT, this overhang not with mRNA complementary, positive-sense strand 3' is held and more easily unwinds, thus increase its silence efficiency.
Above-mentioned S100A9siRNA sequence can be used for the medicine preparing treatment nasopharyngeal carcinoma.
The present invention has following advantage:
(1) siRNA of suppression S100A9 genetic expression provided by the invention, can effective reticent S100A9 gene, lowers the expression of S100A9 gene.
(2) by lowering the expression of S100A9 gene, study its impact on MMP7 genetic expression and cell migration function in nasopharyngeal carcinoma cell CNE1, find that the expression of S100A9siRNA to MMP7 gene has certain restraining effect, nasopharyngeal carcinoma cell shift function can be made to weaken, therefore can be applied in the research for the treatment of medicine for nasopharyngeal.
Accompanying drawing explanation
Examples of the present invention will be described by way of reference to the accompanying drawings, wherein:
Fig. 1 is the siRNA transfection efficiency figure of volume ratio Lipofectamine 2000:siRNA=1:3.
Fig. 2 is the expression level figure of GAPDH gene in fluorescence quantitative PCR detection positive controls (GAPDH), negative control group (N.C.).
Fig. 3 is the expression level figure of S100A9 gene in fluorescence quantitative PCR detection S100A9siRNA1 group, S100A9siRNA2 group, S100A9siRNA3 group, negative control group (N.C.).
Fig. 4 is the expression level figure of S100A9 gene in fluorescence quantitative PCR detection S100A9siRNA3 group, blank group, negative control group (N.C.), control liposome group.
Fig. 5 is the expression level figure of MMP7 gene in fluorescence quantitative PCR detection S100A9siRNA3 group, blank group, negative control group (N.C.), control liposome group.
Fig. 6 is the cell cut figure of 0h, 24h, 48h, 72h after S100A9siRNA3 group cut.
Fig. 7 is the cell cut figure of 0h, 24h, 48h, 72h after blank group cut.
Fig. 8 is the cell cut figure of 0h, 24h, 48h, 72h after negative control group (N.C.) cut.
Fig. 9 is the cell cut figure of 0h, 24h, 48h, 72h after control liposome group cut.
Embodiment
Below by way of embodiment and accompanying drawing, the invention will be further described.
(1) design and synthesis of S100A9siRNA:
According to siRNA principle of design, for the mRNA sequence of S100A9 gene, design 3 pairs of siRNA sequences.Design procedure is: (1) utilizes the Gene database of NCBI, finds the mRNA sequence of S100A9, and it is NM_002965.3 at the ACCESSION of NCBI; (2) utilize WI siRNA Selection Program (http://sirna.wi.mit.edu/) design tool, design 3 pairs of siRNA sequences for coding region different positions; (3) utilize the BLAST of NCBI to analyze, result show these 3 couples of siRNA can not with other gene order homologies, the sequence of described 3 couples of siRNA is as follows:
S100A9siRNA1:
Positive-sense strand: 5'-GCAGCUGGAACGCAACAUA-3'(SEQ ID NO.1)
Antisense strand: 5'-UAUGUUGCGUUCCAGCUGC-3'(SEQ ID NO.2)
S100A9siRNA2:
Positive-sense strand: 5'-CCACCAAUACUCUGUGAAG-3'(SEQ ID NO.3)
Antisense strand: 5'-CUUCACAGAGUAUUGGUGG-3'(SEQ ID NO.4)
S100A9siRNA3:
Positive-sense strand: 5'-GCUUCGAGGAGUUCAUCAU-3'(SEQ ID NO.5)
Antisense strand: 5'-AUGAUGAACUCCUCGAAGC-3'(SEQ ID NO.6)
Above-mentioned each siRNA 3' end have two dangle base dTdT, this pendency base not with mRN A complementary, can silence efficiency be increased.
Above-mentioned siRNA synthesizes by Shanghai JiMa pharmacy Technology Co., Ltd.
(2) cultivation of nasopharyngeal carcinoma cell CNE1:
Nasopharyngeal carcinoma cell CNE1 is inoculated in volume fraction be 10% foetal calf serum, containing in antibiotic 1640 substratum, be placed in 37 DEG C, volume fraction be 5%CO
2in incubator, cultivate under saturated humidity, within every 3 days, go down to posterity once, select the cell of logarithmic phase to test.
(3) transfection of nasopharyngeal carcinoma cell CNE1:
(1) experimental design: experiment is divided into 5 groups, is respectively S100A9siRNA1 group, S100A9siRNA2 group, S100A9siRNA3 group, negative control group (N.C.), positive controls (GAPDH).
Wherein, the sequence of the siRNA of negative control group (N.C.) is:
Positive-sense strand: 5'-GCGACGAUCUGCCUAAGAU-3'(SEQ ID NO.7)
Antisense strand: 5'-AUCUUAGGCAGAUCGUCGC-3'(SEQ ID NO.8)
The sequence of the siRNA of positive controls (GAPDH) is:
Positive-sense strand: 5'-GUAUGACAACAGCCUCAAG-3'(SEQ ID NO.9)
Antisense strand: 5'-CUUGAGGCUGUUGUCAUAC-3'(SEQ ID NO.10)
(2) optimization of transfection conditions: with the negative control FAM-siRNA being marked with fluorescence, judge transfected condition by the cell quantity observed with fluorescence under fluorescent microscope, optimizes transfection conditions, evaluates transfection efficiency.Day before transfection, by cell with 0.5 × 10
5individual cell density is inoculated in 24 orifice plates, substratum adopts volume fraction to be the foetal calf serum of 10%, not containing antibiotic 1640 substratum, transfection reagent Lipofectamine 2000:siRNA is 1:1 by volume, 1:2, 1:3, the ratio transfectional cell respectively of 1:4, often group establishes two multiple holes, transfection method operates according to Lipofectamine 2000 specification sheets, fluorescence microscopy Microscopic observation transfection efficiency, when the volume ratio of Lipofectamine 2000:siRNA is 1:3 and 1:4 as can be seen from the results, transfection is better, transfection wherein when Lipofectamine 2000:siRNA volume ratio is 1:3 as shown in Figure 1.Test from the angle Selection volume ratio Lipofectamine 2000:siRNA=1:3 saving reagent.
(3) transfection:
According to best transfection conditions (volume ratio Lipofectamine 2000:siRNA=1:3), each group of CNE1 cell is pressed 3 × 10
5individual cell density is inoculated in 6 orifice plates, and substratum adopts volume fraction to be 10% foetal calf serum, not containing antibiotic 1640 substratum.Add 5 μ l Lipofectamine 2000,300pmol siRNA in every hole, transfection method operates according to Lipofectamine 2000 specification sheets.
(4) ordered sequence of fluorescence quantitative PCR method screening S100A9siRNA:
(1) 24h after transfection, extract each group of cell total rna (the extraction RNA specification sheets with reference to Axygen company), the RNA row agarose gel electrophoresis extracted, to check RNA integrity, measures A260/A280, A260/A230 and concentration with trace dna detector.
(2) total serum IgE of extraction is carried out removal and reverse transcription reaction (the reference TaKaRa PrimeScript of genomic dna
tMrT reagent Kit with gDNA Eraser specification sheets), obtain cDNA for subsequent use.
(3) cDNA adopting each group of reverse transcription to obtain carries out quantitative fluorescent PCR reaction (with reference to Roche FastStart Universal SYBR Green Master (ROX) specification sheets), reaction conditions is: 95 DEG C of 10min, 95 DEG C of 15s, 60 DEG C of 1min, 40 circulations, use β-actin gene as reference gene, the relatively expression of positive controls (GAPDH) and the middle GAPDH gene of negative control group (N.C.), the expression of S100A9 gene in each group.The primer sequence is:
S100A9 upstream primer: 5'-TGGAGGACCTGGACACAAATG-3'(SEQ ID NO.11), downstream primer: 5'-TCGTCACCCTCGTGCATCTT-3'(SEQ ID NO.12).
β-actin upstream primer: 5'-CAGGCACCAGGGCGTGAT-3'(SEQ ID NO.13), downstream primer: 5'-TAGCAACGTACATGGCTGGG-3'(SEQ ID NO.14).
GAPDH upstream primer: 5'-TGCACCACCAACTGCTTAGC-3'(SEQ ID NO.15), downstream primer: 5'-GGCATGGACTGTGGTCATGAG-3'(SEQ ID NO.16).
(4) fluorescence quantitative PCR detection result as Figure 2-3: the expression first detecting GAPDH gene in positive controls (GAPDH) and negative control group (N.C.), the results are shown in Figure 2, the expression amount of the GAPDH gene of positive controls (GAPDH) is all remarkable in negative control group (N.C.) (P<0.05), explanation reaction system is stablized, the links such as transfection, RNA extraction all meet requirement of experiment, and other each groups that obtain the same period may be used for the expression comparing S100A9 gene.
Then, the expression of S100A9 gene in each group is detected.Each group of S100A9siRNA is compared with negative control group (N.C.), as shown in Figure 3, three groups of sequences all have suppression (P<0.05) in various degree to the expression of S100A9 gene, and it is the most remarkable to decline with the S100A9 gene expression dose of S100A9siRNA3 group, shows that S100A9siRNA provided by the invention effectively can suppress the expression of S100A9 gene.
(5) fluorescence quantitative PCR method detects the expression of S100A9 gene in downward nasopharyngeal carcinoma cell CNE1 to the impact of MMP7 genetic expression
(1) experimental design: experiment is divided into 4 groups, is respectively S100A9siRNA3 group (SEQ ID NO.5, SEQ ID NO.6), negative control group (N.C.), blank group, control liposome group.Wherein the sequence of negative control group (N.C.) is shown in SEQ ID NO.7 and SEQ ID NO.8.
(2) transfection: by each group of CNE1 cell by 3 × 10
5individual cell density is inoculated in 6 orifice plates, substratum adopts volume fraction to be the foetal calf serum of 10%, not containing antibiotic 1640 substratum, transfection S100A9siRNA3 respectively, negative control group (N.C.) sequence, blank group is without the need to transfection (replacing with equivalent substratum), and control liposome group only adds the Lipofectamine 2000 with each group of equivalent, residual content substratum is supplied, and transfection method is with aforementioned.
(3) expression of MMP7 gene is detected
First with the expression of S100A9siRNA3 group, negative control group (N.C.), blank group, control liposome group detection S100A9 gene; Then with the expression of S100A9siRNA3 group, negative control group (N.C.), blank group, control liposome group detection MMP7 gene.The primer sequence is: MMP7 upstream primer: 5'-GGAACAGGCTCAGGACTATCTC-3'(SEQ ID NO.17), MMP7 downstream primer: 5'-CAACATCTGGCACTCCACA-3'(SEQ ID NO.18).
(4) fluorescence quantitative PCR detection result as shown in Figure 4: the expression amount of the S100A9 gene of S100A9siRNA3 group is significantly lower than negative control group (N.C.), blank group, control liposome group (P<0.05), negative control group (N.C.), blank group, the difference (P>0.05) that compares between control liposome group that there are no significant, illustrate that S100A9siRNA provided by the invention effectively can suppress the expression of S100A9 gene, and all there is statistical significance with each control group difference, may be used for the expression detecting MMP7 gene.
Then, detect the expression of MMP7 gene in each group, its result as shown in Figure 5.The expression amount of the MMP7 gene of S100A9siRNA3 group is lower than negative control group (N.C.), blank group, control liposome group (P<0.05), the difference (P>0.05) that compares between negative control group (N.C.), blank group, control liposome group that there are no significant, after showing the expression of downward S100A9 gene, the expression level of MMP7 gene has decline to a certain degree.
(6) impact of the expression on cell migration function of S100A9 gene in nasopharyngeal carcinoma cell CNE1 is lowered:
(1) experimental design: experiment is divided into 4 groups, respectively S100A9siRNA3 group (SEQ ID NO.5, SEQ ID NO.6), negative control group (N.C.), blank group, control liposome group.Wherein the sequence of negative control group (N.C.) is shown in SEQ ID NO.7 and SEQ ID NO.8.
(2) cell scratch experiment: with marker pen at the 6 orifice plate back sides, compares with ruler and draws equidistant 5 horizontal lines equably, by cell by 3 × 10
5individual cell density is inoculated in 6 orifice plates, after 24h, cell (transfection method is the same) is respectively organized in transfection, often group establishes 3 multiple holes, with the horizontal line cut of aseptic 200 μ l rifle heads perpendicular to behind after transfection 24h, PBS washes 3 times, remove the dead cell under drawing, add serum free medium, put back to 37 DEG C, volume fraction is 5%CO
2incubator is cultivated, respectively at 0h, 24h, 48h, 72h after cut, and measurement scratch width of taking pictures, the difference of cut healing between more each group.
(3) cell scratch experiment result as Figure 6-9: 24h after cut, S100A9siRNA3 group (Fig. 6) cell migration degree is more weak, cut defect place has no obvious reparation substantially, blank group (Fig. 7), negative control group (N.C.) (Fig. 8) and control liposome group (Fig. 9) cell migration ability are comparatively strong, and scratch width obviously narrows; 48h and 72h after cut, along with the disappearance of siRNA effect, S100A9siRNA3 group extent of migration is slightly strong, and cut defect place repairs to some extent, and negative control group (N.C.), blank group and control liposome group cell fill up scored area substantially.
Difference (P>0.05) that between negative control group (N.C.), blank group and control liposome group, there are no significant, and S100A9siRNA3 group is compared with negative control group (N.C.), blank group and control liposome group, difference has statistical significance (P<0.05), after illustrating that S100A9siRNA of the present invention lowers the expression of S100A9 gene, the shift function of nasopharyngeal carcinoma cell CNE1 can be made obviously to weaken.
Claims (3)
1. suppress the siRNA of S100A9 genetic expression, it is characterized in that its sequence is:
Positive-sense strand: 5'-GCUUCGAGGAGUUCAUCAU-3'
Antisense strand: 5'-AUGAUGAACUCCUCGAAGC-3'.
2. the siRNA of suppression S100A9 genetic expression according to claim 1, is characterized in that: the 3' end of described siRNA sequence overhangs two dTdT, this overhang not with mRNA complementary.
3. the siRNA of suppression S100A9 according to claim 1 and 2 genetic expression, is characterized in that the application of described siRNA in treatment medicine for nasopharyngeal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410541184.2A CN104293788A (en) | 2014-10-14 | 2014-10-14 | SiRNA inhibiting expression of gene S100A9 and application of siRNA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410541184.2A CN104293788A (en) | 2014-10-14 | 2014-10-14 | SiRNA inhibiting expression of gene S100A9 and application of siRNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104293788A true CN104293788A (en) | 2015-01-21 |
Family
ID=52313741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410541184.2A Pending CN104293788A (en) | 2014-10-14 | 2014-10-14 | SiRNA inhibiting expression of gene S100A9 and application of siRNA |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104293788A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110225984A (en) * | 2016-09-07 | 2019-09-10 | 科技研究局 | Identify the method and therapeutic choice of risk of cancer |
| CN111840561A (en) * | 2020-08-11 | 2020-10-30 | 大连医科大学附属第一医院 | Application of S100A9 inhibitor in preparation of medicine for treating pancreatitis |
| CN115120727A (en) * | 2022-06-16 | 2022-09-30 | 甘肃农业大学 | Application of S100A9 inhibitor in preparation of drugs for preventing and treating C-type clostridium perfringens infectious diarrhea |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004106519A2 (en) * | 2003-06-03 | 2004-12-09 | Switch Biotech Ag | Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids |
| CN104293789A (en) * | 2014-10-14 | 2015-01-21 | 广西医科大学 | siRNA for inhibiting gene expression of S100A8 and application thereof |
-
2014
- 2014-10-14 CN CN201410541184.2A patent/CN104293788A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004106519A2 (en) * | 2003-06-03 | 2004-12-09 | Switch Biotech Ag | Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids |
| CN104293789A (en) * | 2014-10-14 | 2015-01-21 | 广西医科大学 | siRNA for inhibiting gene expression of S100A8 and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| LIN‑LIN YAN ET AL.: "Effects of silencing S100A8 and S100A9 with small interfering RNA on the migration of CNE1 nasopharyngeal carcinoma cells", 《ONCOLOGY LETTERS》 * |
| 何芹: "钙结合蛋白S100A8和S100A9对鼻咽癌侵袭和迁移的影响", 《WWW.CNKI.NET》 * |
| 吴慧玲 等: "S100蛋白表达与鼻咽癌临床关系的研究", 《中国现代医药杂志》 * |
| 李美香 等: "S100A9蛋白在鼻咽癌中的表达及其临床意义", 《解剖科学进展》 * |
| 闫琳琳: "siRNA沉默S100A8与S1_省略_鼻咽癌细胞CNE1迁移功能的影响", 《WWW.CNKI.NET》 * |
| 韩冉冉: "S100A8和S100A9在鼻咽癌中的表达及临床意义", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110225984A (en) * | 2016-09-07 | 2019-09-10 | 科技研究局 | Identify the method and therapeutic choice of risk of cancer |
| US11680298B2 (en) | 2016-09-07 | 2023-06-20 | Agency For Science, Technology And Research | Method of identifying risk of cancer and therapeutic options |
| CN111840561A (en) * | 2020-08-11 | 2020-10-30 | 大连医科大学附属第一医院 | Application of S100A9 inhibitor in preparation of medicine for treating pancreatitis |
| CN111840561B (en) * | 2020-08-11 | 2022-03-04 | 大连医科大学附属第一医院 | Application of S100A9 inhibitor in preparation of medicine for treating pancreatitis |
| CN115120727A (en) * | 2022-06-16 | 2022-09-30 | 甘肃农业大学 | Application of S100A9 inhibitor in preparation of drugs for preventing and treating C-type clostridium perfringens infectious diarrhea |
| CN115120727B (en) * | 2022-06-16 | 2024-02-23 | 甘肃农业大学 | Application of S100A9 inhibitor in preparation of medicine for preventing and treating clostridium perfringens infection diarrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | LncRNA Gas5 acts as a ceRNA to regulate PTEN expression by sponging miR-222-3p in papillary thyroid carcinoma | |
| Jin et al. | Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells | |
| Laios et al. | Potential role of miR-9 and miR-223 in recurrent ovarian cancer | |
| Tano et al. | MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes | |
| Wang et al. | Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK | |
| Li et al. | Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23 | |
| Peña-Chilet et al. | MicroRNA profile in very young women with breast cancer | |
| Ni et al. | Downregulation of miR‐106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2 | |
| Yang et al. | LncRNA SNHG12 regulated the proliferation of gastric carcinoma cell BGC-823 by targeting microRNA-199a/b-5p. | |
| Wang et al. | Prognostic and biological significance of microRNA‐127 expression in human breast cancer | |
| Guo et al. | MiR-135a-5p represses proliferation of HNSCC by targeting HOXA10 | |
| Wang et al. | Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells | |
| US20140322354A1 (en) | Tissue & blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer | |
| Yoon et al. | NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal | |
| Zhang et al. | LncRNA PTCSC3 is a biomarker for the treatment and prognosis of gastric cancer | |
| Zhang et al. | Rab5a is overexpressed in oral cancer and promotes invasion through ERK/MMP signaling | |
| Liang et al. | LINC00922 accelerates the proliferation, migration and invasion of lung cancer via the miRNA-204/CXCR4 axis | |
| Yang et al. | STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo | |
| Cui et al. | Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A | |
| Xu et al. | A genome-wide comprehensively analyses of long noncoding RNA profiling and metastasis associated lncRNAs in renal cell carcinoma | |
| Zhu et al. | Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer | |
| Wang et al. | Circ-ZDHHC5 accelerates esophageal squamous cell carcinoma progression in vitro via miR-217/ZEB1 axis | |
| Ma et al. | Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation | |
| Lin et al. | Long non-coding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-1246. | |
| Yan et al. | SPAG9 is involved in hepatocarcinoma cell migration and invasion via modulation of ELK1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |